Cardiac Hypertrophy Is Inhibited by a Local Pool of cAMP Regulated by Phosphodiesterase 2
- 25 September 2015
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 117 (8), 707-719
- https://doi.org/10.1161/circresaha.114.305892
Abstract
Rationale: Chronic elevation of 3′-5′-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodeling and cardiac hypertrophy. However, enhancement of particular aspects of cAMP/protein kinase A signaling seems to be beneficial for the failing heart. cAMP is a pleiotropic second messenger with the ability to generate multiple functional outcomes in response to different extracellular stimuli with strict fidelity, a feature that relies on the spatial segregation of the cAMP pathway components in signaling microdomains. Objective: How individual cAMP microdomains affect cardiac pathophysiology remains largely to be established. The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in shaping local changes in cAMP. Here we investigated the effect of specific inhibition of selected PDEs on cardiac myocyte hypertrophic growth. Methods and Results: Using pharmacological and genetic manipulation of PDE activity, we found that the rise in cAMP resulting from inhibition of PDE3 and PDE4 induces hypertrophy, whereas increasing cAMP levels via PDE2 inhibition is antihypertrophic. By real-time imaging of cAMP levels in intact myocytes and selective displacement of protein kinase A isoforms, we demonstrate that the antihypertrophic effect of PDE2 inhibition involves the generation of a local pool of cAMP and activation of a protein kinase A type II subset, leading to phosphorylation of the nuclear factor of activated T cells. Conclusions: Different cAMP pools have opposing effects on cardiac myocyte cell size. PDE2 emerges as a novel key regulator of cardiac hypertrophy in vitro and in vivo, and its inhibition may have therapeutic applications.Keywords
This publication has 52 references indexed in Scilit:
- PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosomeThe Journal of cell biology, 2012
- β-Adrenergic Receptor Stimulation and Activation of Protein Kinase A Protect Against α1-Adrenergic–Mediated Phosphorylation of Protein Kinase D and Histone Deacetylase 5Journal of Cardiac Failure, 2011
- Regulation by phosphodiesterase isoforms of protein kinase A-mediated attenuation of myocardial protein kinase D activationBasic Research in Cardiology, 2010
- PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophyProceedings of the National Academy of Sciences, 2010
- Isoform- and tissue-specific regulation of the Ca2+-sensitive transcription factor NFAT in cardiac myocytes and heart failureAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- (d)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase IαBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2009
- The mAKAPβ scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurinJournal of Molecular and Cellular Cardiology, 2009
- Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsEuropean Heart Journal, 2009
- AKAP complex regulates Ca 2+ re‐uptake into heart sarcoplasmic reticulumEMBO Reports, 2007
- Phosphorylation of serine 1928 in the distal C-terminal domain of cardiac Ca V 1.2 channels during β1-adrenergic regulationProceedings of the National Academy of Sciences, 2006